Table 3.
Significant Differences in Gene Mutation Frequencies Between ERBB2/3‐Mutated Colonic and Rectal mCRC
| Colonic | ||||||
|---|---|---|---|---|---|---|
| Gene | All | ERBB2+ | Fisher Exact Test P a | ERBB3+ | Fisher Exact Test P a | Fisher Exact Test P b |
| TP53 | 74.9% | 82.3% | <.001 | 60.0% | <.001 | <.00001 |
| APC | 75.3% | 72.7% | NS | 80.8% | NS | NS |
| KRAS | 51.6% | 28.2% | <.00001 | 62.5% | <.02 | <.00001 |
| PIK3CA | 18.5% | 14.4% | <.05 | 24.2% | NS | <.02 |
| SMAD4 | 15.4% | 15.7% | NS | 16.7% | NS | NS |
| SOX9 | 10.2% | 6.7% | <.05 | 11.8% | NS | NS |
| FBXW7 | 9.4% | 12.7% | <.05 | 18.3% | <.01 | NS |
| MYC | 9.0% | 11.3% | NS | 4.2% | NS | <.02 |
| BRAF | 8.6% | 3.6% | <.001 | 5.0% | NS | NS |
| PTEN | 8.1% | 8.3% | NS | 14.2% | <.05 | NS |
| ARID1A | 6.8% | 9.1% | NS | 14.2% | <.01 | NS |
| FAM123B | 6.4% | 4.7% | NS | 20.0% | <.00001 | <.00001 |
| BCL2L1 | 5.0% | 3.1% | NS | 0.0% | <.05 | NS |
| RNF43 | 4.4% | 6.7% | <.05 | 12.5% | <.001 | NS |
| NRAS | 4.3% | 1.7% | <.01 | 3.3% | NS | NS |
| MLL2 | 3.6% | 5.0% | NS | 8.3% | <.02 | NS |
| NF1 | 2.5% | 3.6% | NS | 5.8% | <.05 | NS |
| TOP2A | 1.2% | 23.5% | <.00001 | 2.4% | NS | <.00001 |
| CDK12 | 1.0% | 7.0% | <.00001 | 3.3% | <.05 | NS |
| PIK3R1 | 3.6% | 5.8% | <.05 | 8.3% | <.02 | NS |
| ASXL1 | 3.6% | 4.5% | NS | 12.5% | <.0001 | <.01 |
| LRP1B | 3.6% | 4.4% | NS | 9.2% | <.01 | NS |
| MAP2K4 | 2.7% | 4.4% | <.05 | 3.3% | NS | NS |
| BCORL1 | 2.2% | 3.9% | <.05 | 7.5% | <.01 | NS |
| MSH6 | 2.0% | 2.8% | NS | 10.8% | <.00001 | <.0001 |
| MLH1 | 1.1% | 1.9% | NS | 7.5% | <.00001 | <.01 |
| MSH2 | 1.1% | 3.6% | <.001 | 5.0% | <.01 | NS |
| PMS2 | 0.3% | 1.7% | <.001 | 2.5% | <.01 | NS |
| Rectal | ||||||
|---|---|---|---|---|---|---|
| Gene | All | ERBB2+ | Fisher Exact Test P a | ERBB3+ | Fisher Exact Test P a | Fisher Exact Test P b |
| TP53 | 79.6% | 80.6% | NS | 67.9% | NS | NS |
| APC | 77.7% | 65.7% | <.05 | 57.1% | <.02 | NS |
| KRAS | 53.0% | 22.4% | <.00001 | 53.6% | NS | <.01 |
| PIK3CA | 12.9% | 13.4% | NS | 25.0% | NS | NS |
| SMAD4 | 12.3% | 11.9% | NS | 28.6% | <.02 | NS |
| SOX9 | 8.9% | 0.0% | <.02 | 5.0% | NS | NS |
| ARID1A | 8.2% | 10.4% | NS | 21.4% | <.05 | NS |
| TOP2A | 0.6% | 9.8% | <.00001 | 0.0% | NS | NS |
| CDK12 | 0.6% | 6.1% | <.001 | 0.0% | NS | NS |
| PIK3R1 | 2.3% | 0.0% | NS | 10.7% | <.05 | <.05 |
| BCORL1 | 0.9% | 3.0% | NS | 7.1% | <.05 | NS |
| SMAD2 | 3.3% | 6.0% | NS | 14.3% | <.02 | NS |
| FAM123B | 5.2% | 4.5% | NS | 3.6% | NS | NS |
Abbreviations: APC, adenomatous polyposis coli; ARID1A, AT‐rich interaction domain 1A; ASXL1, additional sex combs‐like 1; BCL2L1, Bcl‐2‐like 1; BCORL1, BCL6 corepressor‐like 1; CDK12, cyclin‐dependent kinase 12; FBXW7, F‐box/WD repeat‐containing protein 7; LRP1B, low‐density lipoprotein receptor‐related protein 1B; MAP2K4, mitogen‐activated protein kinase 4; mCRC, metastatic colorectal cancer; MLH1, MutL homolog 1; MLL2, mixed linage leukemia gene 2; MSH2, mutS homolog 2; MSH6, mutS homolog 6; NF1, neurofibromatosis type 1; NS, not significant; PIK3CA, phosphatidylinositol 3‐kinase; PIK3R1, phosphoinositide‐3‐kinase regulatory subunit 1; PTEN, phosphatase and tensin homolog; RNF43, ring finger protein 43; SOX9, SRY‐box 9; TOP2A, topoisomerase (DNA) II alpha; TP53, tumor protein p53.
Significance values for the difference in frequency between all mCRC and ERBB2‐mutated or ERBB3‐mutated samples, respectively.
Significance values for the difference in frequency between ERBB2‐mutated and ERBB3‐mutated samples.